Adult
Conditions
Interventions
Functional food Daily dosage: 1 cupsule/day Duration: 84 days
Placebo food Daily dosage: 1 cupsule/day Duration: 84 days
Sponsors
Yamada Bee Company, Inc.
Research Center for Immunological Analysis, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy Japanese men and women aged between 20 and 65 years at the time of consent. 2) Individuals who have been fully informed about the purpose and details of the study, have provided written consent, and voluntarily wish to participate. 3) Individuals deemed eligible by the principal investigator based on a comprehensive judgment
Exclusion criteria
Exclusion criteria: 1) Individuals with a history of or current allergy to lactic acid bacteria. 2) Regular users of medications or supplements (including health-functional foods) that may affect the study results. 3) Individuals with a history of major gastrointestinal surgeries, such as gastrectomy, intestinal suture, or bowel resection. 4) Individuals with severe hepatic dysfunction, renal, cardiac, or organ disorders, diabetes, or other serious illnesses. 5 Individuals undergoing medication treatment for chronic diseases that may affect the study results or are expected to receive such treatment during the study period. 6) Individuals unable to maintain a regular lifestyle during the study period. 7) Individuals engaged in shift work. 8) Individuals who donated more than 200 mL of blood within 4 weeks or more than 400 mL of blood within 3 months prior to the start of the study. 9) Smokers (including electronic cigarettes). 10) Pregnant women or those planning to become pregnant. 11) Individuals who participated in another clinical study and received an intervention within the last 3 months. 12) Individuals deemed unsuitable for study participation by the principal investigator. 13) Regular users of medications such as phenytoin, antidepressants, analgesics, antihypertensives, antihistamines, or anti-Parkinsonian drugs. 14) Individuals planning to receive vaccines (influenza/COVID-19) during the study period or who received a vaccine within 6 months prior to the study's start.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pDC activity | — |
Secondary
| Measure | Time frame |
|---|---|
| IFN-alpha, mDC1/mDC2 activity | — |
Countries
Japan
Contacts
Public ContactAkio Ohkuma
Research Center for Immunological Analysis, Inc. -
Outcome results
None listed